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PREVIOUS experimental studies in rodents and in dogs have established the efficacy of FK 506 in controlling 
the immunologic events following small bowel or multi vis-
cera! transplantation. '-s To complete the assessment of 
FK 506 in experimental small bowel transplantation. we 
present here our experience with the frequently used swine 
model. 
MATERIALS AND METHODS 
Fifty-two outbred female piglets (mean weight 29.3 ~ :2.1 hg) were 
used. half as donors and half as recipients. Unlike the dog model. 
total orthotopic small bowel transplantation in the swine is not 
possible with the exchange of grafts between the donor and the 
recipient because of vascular anatomy. 
Under general anesthesia with isofluorane. the entire donor's 
small bowel except the duodenum and S cm of the terminal ileum 
was isolated with its vascular pedicle and excised. The graft was 
perfused through the aorta with cold University of Wisconsin 
solution. The transplantation technique was essentially the same 
as that originally described by Kumlin et al.I> The superior 
mesenteric artery and the superior mesenteric vein were anasto-
mosed end-to-cnd. The proximal intestinal continuity was re-
stored with a side-to-side anastomosis between the recipient 
duodenum and the end of the first jejunal loop of the graft. A 
IO-cm segment of the graft-proximal jejunum was exteriorized, as 
a stoma. for visual monitoring and postoperative mucosal biop-
\ies. The distal intestinal continuity was obtained with an end-to-
end or a side-to-side anastomosis between the extremity of the 
graft ileum and the last 5 em of recipient ileum. A gastrostomy was 
performed to allow enteral feeding and oral FK 506 administra-
tion. 
The animals were divided into five groups. according to treat-
ment lTable 11. Five animals (one of each group I who died within 
IS days from various technical causes were excluded from the final 
analysis. Treatment was maintained until death occurred. The 
animals who became lethargic or lost more than 40% of their 
preoperative body weight were killed with an anesthesia injection. 
FK 506 trough levels were delennined from whole blood by a 
Table 1. 
FK506 Mean Besl 
SUMVaI survival 
Group No. mgtkg d Route Steroids (d) (d) 
1 3 12 = 1 13 
2 5 0.1 1M Yes' 12 = 3 17 
3 5 0.15 1M Yes' 18:!: 1 19 
4 8 0.2-0.3 IMf No; 27:: 6 35 
5 5 0.3 1M + OS§ No: 32 !: 12 45 
'BoluS at repertuSIOn (500 mg IV). recyde. maintenance dOse (10 mg kQld 1M) . 
• After 3 to 7 d of 0.2 tngkg d. the doSe was Increased to 0.3 mg. kgd. 
I Bolus at reoerfuslon 1500 mg IV). 
'FK 506 was admtnlstereo 1M for Ihe fIrst 2 postooeratlVe weekS. then orally at 
the same doSe. 
fluorescence polarization immunoassay (FPIA. TOX-Abbott). 
Antibiotic prophylaxis consisted of ceftazidime 3 g/d. 
Postoperative monitoring was based on observations of the 
clinical course. stools. appearance of the stoma. body weight. 
blood chemistries. body temperature. blood cultures. and mucosal 
biopsies. Tissues obtained from stomal biopsies or at postmortem 
examination were fixed with 10% buffered fonnalin and stained 
with hematoxylin-eosin. Histologic features of acute rejection are 
reported in detail in another part of this issue.7 Maltose absorption 
test (1 g/kg) was performed periodically using the modified method 
of Billiar et al. K 
RESULTS 
The best mean survival rate occurred in group 5 (32 :!: 12 
days) with two animals that survived more than 6 weeks. 
One animal is still alive in good condition at 23 days. 
Causes of death were emaciation (two cases) and strangu-
lated obstruction (one case). In group 4 the mean survival 
was 27 :!: 6.5 days. Lethal emaciation ~and sepsis caused 
the death of all animals but one. which died from acute 
rejection. 
All untreated recipients (group I) died of acute rejection 
within 12 days (mean 12 :!: I days) as well as animals of 
group 2 (mean 12 :!: 3 days). In group 3 survival was 
prolonged to a mean of 18 :!: I days. All recipients of this 
latter group experienced acute rejection. which caused the 
death in 50% of the cases whereas in the other 50% it 
contributed to the development of fatal sepsis. The five 
animals (one for each group) excluded from the final 
analysis died between days 3 and 8 from technical compli-
cations such as volvulus (two cases). arterial thrombosis 
(two cases). and intraperitoneal hemorrhage (one case). 
Clinical or histologic graft-vs-host disease (GVHDl was 
not seen in any of the animals. 
A detailed evaluation of the incidence and the severity of 
the rejection episodes in groups I to 4 is reported in 
another part of this issue.7 The results of maltose absorp-
tion test are also explained elsewhere in this issue." 
FK 506 trough levels for each group are shown in Fig I. 
They were at a very low range in groups :2 and 3 with a 
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FK 506 DOSE: 0.1 1M 
-...... 
18 IV V 
0.15 IlIA 0.2-0.3 IlIA 0.3 1M-OS 
Fig 1. FK 506 levels in each study group, 
mean of 1.7 :!: 1.1 ng/mL and 6.8 :!: 4.2 nglmL. respec-
tively. In groups 4 and 5. FK 506 levels were increased to 
a mean of 26.1 :!: 13.4 ng/mL and 36.2 :!: 15.3 ng/mL. 
respectively. Interestingly, in group 4 the peak level was 
reached between the first and the second week in accor-
dance with the increased intramuscular OM) dose (see 
Table I). In group 5 the peak level was obtained during the 
first week and, after the conversion to the oral route, it 
decreased and was maintained stable to a mean of 24.1 :!: 
6.2 ng/mL. 
DISCUSSION 
Previous experimental studies have assessed the feasibility 
of small bowel transplantation in pigs. III Long-term surviv-
als have been achieved with cyclosporine (CyA)-based 
immunosuppression. ".12 However. acute rejection was 
controlled with such high doses of Cy A. corresponding to 
almost five times those tolerated by humans. II . I :! 
FK 506 has already been tested in a large animal model. 
the dog. 5 This is the first study on pigs to assess the 
efficacy of FK 506 for small bowel transplantation. Four 
different dosages of FK 506 were tested. The choice of the 
1M route was made to simplify the postoperative manage-
ment of the animals. Pharmacokinetic studies demon-
strated that after 1M injection the drug is well absorbed and 
its 12-hour kinetic profile curve is almost equivalent to a 
continuous I V administration of a lower dose (unpublished 
datal. 
Doses of FK 506 of 0.\ or 0.\5 mglkgld 1M were not 
sufficient to prevent acute rejection. even if steroids were 
added. When FK 506 was given at doses of &.2 mg/kg/d. 
rejection still occurred within the first 2 weeks. For this 
reason. the immunosuppressive protocol was modified in 
group 4 animals and. after a 3-day course of 1M FK 506 at 
0.2 mlUklUd. the dose was increased 10 n.3 mg/kg/d. 
Survival improved and most of the animals rcached a 
month. However emaciation associated in most cases with 
1607 
sepsis became the common cause of death in this group. 
Only one recipient developed acute rejection. At the 
postmortem examination. all other animals were rejection 
free but five of seven presented scattered polypoid lesions 
in the graft. a possible sign of Iymphoproliferative hyper-
plasia.7 No other similar lesions were found in other 
organs. 
After a loading dose of 0.3 mg/kg/d. conversion to the 
oral route was made after 7 to 10 days in group 5 animals. 
Of the five recipients. two died for technical complications 
whereas two others registered the best survival in the 
present study: 42 and 45 days. respectively. The cause of 
death of these last two animals is still controversial be-
cause the postmortem histologic evaluation is not yet 
available. They maintained normal weight and good ab-
sorptive function (confirmed by the FK 506 trough levels) 
until 5 to 7 days before death and then suddenly worsened 
and died. Both animals had positive blood cultures for 
Streptococcus at the 30th postoperative day. Macroscopic 
signs of severe acute rejection were absent in the graft at 
the postmortem evaluation. However the intestinal wall of 
both grafts appeared thicker when compared with that of 
the recipient intestine. Moreover. FK 506 levels dropped 
significantly after conversion to oral route and this fact 
may have predisposed to chronic rejection. A higher FK 
506 oral dose could be necessary to prolong survival in this 
group. The surviving animal is now being treated with oral 
0.4 mglkg/d. 
Sepsis has been a major problem in the management of 
all animals and it affected survivals significantly. Many 
recipients already had positive blood cultures before sur-
gery. Our opinion based on this early experience is that 
swine is a difficult species for studies in organ transplan-
tation. However. FK 506 can provide powerful immuno-
suppression after small bowel transplantation at the sug-
gested doses (group 4 and 5). allowing a good survival of 
the animals for more than a month. As a consequence. this 
model can be used for morphologic. functional. and immu-
nologic studies. 7.13.14 We think that longer survivals can be 
achieved with better monitoring of FK 506 levels and 
better control of the infectious complications. 
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